Stay updated on Nivolumab for Peripheral T-cell Lymphoma Clinical Trial

Sign up to get notified when there's something new on the Nivolumab for Peripheral T-cell Lymphoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Nivolumab for Peripheral T-cell Lymphoma Clinical Trial page

  1. Check
    2 days ago
    Change Detected
    Summary
    The footer revision identifier changes from v3.7.0 to v3.7.1.
    Difference
    0.2%
    Check dated 2026-10-11T03:09:01.000Z thumbnail image
  2. Check
    9 days ago
    No Change Detected
  3. Check
    16 days ago
    No Change Detected
  4. Check
    23 days ago
    Change Detected
    Summary
    A 403 Forbidden page is now displayed, replacing the study record content. The site header and footer remain visible, signaling an access/permission issue rather than a substantive study data update.
    Difference
    20%
    Check dated 2026-09-20T01:09:53.000Z thumbnail image
  5. Check
    30 days ago
    Change Detected
    Summary
    The study detail text on the page remains unchanged; the provided changes section shows no additions or deletions.
    Difference
    0.1%
    Check dated 2026-09-12T23:42:14.000Z thumbnail image
  6. Check
    37 days ago
    Change Detected
    Summary
    No additions or deletions were recorded. The page content remains as shown in the current version, including the study’s summary and eligibility details.
    Difference
    0.1%
    Check dated 2026-09-05T21:58:32.000Z thumbnail image
  7. Check
    44 days ago
    Change Detected
    Summary
    The page now displays Revision: v3.6.6, replacing the previous v3.6.5. This update reflects an internal revision/build of the page and does not alter the actual trial data, eligibility criteria, or results.
    Difference
    0.1%
    Check dated 2026-08-29T19:50:10.000Z thumbnail image
  8. Check
    65 days ago
    Change Detected
    Summary
    A new site revision tag 'Revision: v3.6.5' is added. A significant portion of the study page content and links (such as Study Documents, results history, eligibility criteria, publications, and contacts) was removed, reducing the amount of study-specific information shown.
    Difference
    19%
    Check dated 2026-08-08T17:18:15.000Z thumbnail image

Stay in the know with updates to Nivolumab for Peripheral T-cell Lymphoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Nivolumab for Peripheral T-cell Lymphoma Clinical Trial page.